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http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, TaiwanBackground/purpose: Carbapenem-resistant Pseudomonas aeruginosa infections have been a
challenge and issue in hospital settings. However, the clinical impact of P. aeruginosa blood
isolates resistant only to carbapenems has never been discussed previously.
Methods: To assess the risk factors and clinical significance of bacteremia caused by carbape-
nem resistance only P. aeruginosa (CROPA), a 6-year retrospective caseecontrol study was
conducted. The CROPA strains were defined as isolates susceptible to ciprofloxacin, antipseu-
domonal penicillins and cephalosporins, and aminoglycosides but resistant to one antipseudo-
monal carbapenem (imipenem or meropenem) or both. The controls were selected among
patients with bacteremia due to P. aeruginosa susceptible to all above classes of antipseudo-
monal antibiotics, which was defined as all-susceptible P. aeruginosa.
Results: Twenty-five patients had at least one blood culture positive for CROPA, and 50 con-
trols had all-susceptible P. aeruginosa bacteremia. CROPA bacteremia had a high 30-day mor-
tality rate (72.0%), as compared to 26.0% for the controls (p < 0.001). Through multivariate
analysis, carbapenem exposure was the only risk factor for developing CROPA bacteremia
(p Z 0.002). A comparison between the surviving and deceased patients with CROPA bacter-
emia showed that nine (50%) of those who died, but none of the survivors, received carbape-
nems as the initial empirical therapy (p Z 0.027).Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, 5
n, Taiwan.
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resistant only to carbapenems, JournConclusion: Carbapenem exposure was associated with emergence of CROPA infections.
Repeated carbapenem use in such patients might increase rates of inappropriate initial empir-
ical treatment and mortality. Prudent carbapenem use is important to reduce the emergence
of CROPA.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Pseudomonas aeruginosa is a leading cause of nosocomial
infections in hospital settings.1 The in-hospital mortality
related to P. aeruginosa bloodstream infections is from
25.5% to 39%.2,3 Imipenem is a mainstay in the treatment of
severe P. aeruginosa infections, but the emergence of
increasing imipenem resistance among clinical P. aerugi-
nosa isolates has become a major concern of clinicians.4,5
The average 30-day mortality of imipenem-resistant P.
aeruginosa bacteremia was up to 41%, and these isolates
were more likely to have cross-resistance to other common
antipseudomonal agents.3,6,7 The mechanisms of carbape-
nem resistance for P. aeruginosa are production of metallo-
b-lactamase, overexpression of efflux, and loss of the outer
membrane protein.8e11 Either production of metallo-b-
lactamase or overexpression of efflux could induce resis-
tance to other antipseudomonal b-lactams.
During a 6-year period from 2004 to 2010, we noted the
emergence of an unusual group of P. aeruginosa strains,
which were resistant only to carbapenems (imipenem,
meropenem, or both) via the disk diffusion method in
accordance with the Clinical and Laboratory Standards
Institute (CLSI) document M100-S22.12 We defined this
phenotype of P. aeruginosa strain as carbapenem
resistance-only P. aeruginosa (CROPA),13 which were sus-
ceptible to all antipseudomonal antibiotics tested (amika-
cin, gentamicin, piperacillin, piperacillinetazobactam,
aztreonam, ceftazidime, cefepime, and ciprofloxacin) but
were resistant to carbapenems (imipenem, meropenem, or
both). The percentage of CROPA strains among all the
clinical P. aeruginosa blood isolates increased from 1.8% to
4.9% during the 6-year period from 2004 to 2010 at our
hospital. The clinical impact of bacteremia caused by these
CROPA strains has never been discussed in the English
literature.
Thus, we conducted a 6-year retrospective caseecontrol
study to address the risk factors and clinical significance of
CROPA bacteremia.Materials and methods
Study site and ethical approval
Chang Gung Memorial Hospital Linkou is a 3715-bed
university-affiliated medical center providing both pri-
mary and tertiary care in northern Taiwan. The ethical
approval for this study was given by the hospital Institu-
tional Review Board with a reference number of 100-0795B.e C-H, et al., Risk factors and clin
al of Microbiology, Immunology aStudy design and patients
A retrospective cohort 1:2 matched caseecontrol study was
conducted to collect cases with P. aeruginosa bacteremia be-
tween October 2004 and October 2010. We identified all the
hospitalized patients with an age 18 years and at least one
blood culture positive for CROPAby searching themicrobiology
laboratory database. Patients were considered cases if they
had symptoms and signs suggestive of systemic infection with
an imipenem or meropenem minimal inhibitory concentration
(MIC) of their first isolate 4 mg/mL.12 The symptoms and signs
of infection included at least two of the following clinical
characteristics: (1) temperature < 36C or > 38C; (2) heart
rate > 90 beats/min; (3) tachypnea: respiratory rate > 20
breaths/min, or arterial partial pressure of carbon
dioxide < 32 mmHg; (4) white blood cell count < 4.0  109
cells/L or > 12.0  109 cells/L; or (5) the presence of >10%
immature neutrophils. The controls were patients hospitalized
during the study period with bacteremia due to P. aeruginosa
susceptible toall the testedantipseudomonalagents, including
amikacin, gentamicin, ciprofloxacin, aztreonam, ceftazidime,
cefepime, piperacillinetazobactam, piperacillin, imipenem,
and meropenem. This type of P. aeruginosa strains were
defined as all-susceptible P. aeruginosa (ASPA) and all the first
isolates had MICs < 4 mg/mL for both imipenem and mer-
openem.12 For each patient with CROPA bacteremia, two
matched controls were selected by a stepwise matching
technique to identify the appropriate control patient matched
to a case for gender, age  5 years, and the year of P. aerugi-
nosa being isolated. Only the first episode of bacteremia was
included for analysis. Patients with polymicrobial bacteremia
were excluded to avoid the influence of multiple pathogens on
the analysis of prognosis.
Data collection and definitions
Patients’ demographics and clinical characteristics were
obtained from their medical records, including age, sex,
and length of hospital stay before P. aeruginosa bacter-
emia, laboratory data, and clinical outcomes. Variables as
risk factors included comorbid illnesses (such as diabetes
mellitus, liver cirrhosis, end-stage renal disease, chronic
obstructive lung disease, solid tumors, hematological ma-
lignancies, and cerebral vascular accident), sources of
bacteremia, Pittsburgh bacteremia scores for disease
severity, and antibiotic exposure prior to bacteremia.
A nosocomial infection was considered if the infection
was not evident until >48 hours of hospitalization. Severity
of illness was evaluated on the 1st day of bacteremia onset
by means of Pittsburgh bacteremia score.14 The sources ofical significance of bacteremia caused by Pseudomonas aeruginosa
nd Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.06.003
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cords, image studies, surgical findings, and microbiologic
evidence. The sources were further categorized into lower
respiratory tract, intra-abdominal sites, urinary tract, skin,
soft tissue, bone, and central venous catheter. If there was
no definite source, it was categorized as primary
bacteremia.
Prior antibiotic exposure was defined as the exposure to
antimicrobial agents for at least 3 consecutive days within 3
months of CROPA bacteremia onset. The following classes
of antibiotics were recorded: penicillin and its derivatives,
aminoglycosides, cephalosporins, antipseudomonal cepha-
losporins, carbapenems, and glycopeptides. The penicillin
class of antibiotics included penicillin, oxacillin,
ampicillin, piperacillin, amoxicillineclavulanate, ampi-
cillinesulbactam, and piperacillinetazobactam. Amino-
glycosides included gentamicin and amikacin.
Cephalosporins included cefazolin, cefuroxime, ceftriax-
one, flomoxef, ceftazidime, cefepime, and cefpirome.
Antipseudomonal cephalosporins included ceftazidime,
cefepime, and cefpirome. Carbapenems included ertape-
nem, imipenem, and meropenem. Fluoroquinolones
included moxifloxacin, levofloxacin, and ciprofloxacin.
Glycopeptides included vancomycin and teicoplanin. Initial
empirical antibiotic treatment was defined as the first
antibiotic prescribed within 72 hours of blood culture
collection, and was classified as appropriate if the antibi-
otic was active in vitro against the identified pathogens.
Microbiologic analysis
Blood cultures were processed in the clinical microbiology
laboratory, using an automated blood culture system
(BACTEC 9240 system; Becton Dickinson Diagnostic Instru-
ment Systems, Sparks, MD, USA). P. aeruginosa isolates
were identified according to routine bacteriological pro-
cedures. Antibiotic susceptibility testing was determined
by the CLSI disk diffusion method.12 The antibiotic disks (BD
Microbiology Systems, Cockeysville, MD, USA) for P. aeru-
ginosa included amikacin, gentamicin, piperacillin, piper-
acillinetazobactam, aztreonam, ceftazidime, cefepime,
imipenem, meropenem, and ciprofloxacin. The control
strain, P. aeruginosa ATCC 27853, was included in each test
run. Interpretation of disk diffusion results was made in
accordance with the CLSI document M100-S22.12 The sus-
ceptibility of P. aeruginosa to imipenem and meropenem
was initially screened with disk-diffusion testing, and was
confirmed by the Etest method according to the manufac-
turer’s instructions (AB Biodisk, Solna, Sweden). The MIC
breakpoint for imipenem and meropenem resistance
was 4 mg/mL (intermediate resistance) and 8 mg/mL
(resistance).12
Statistical analysis
Continuous variables were expressed as mean  standard
deviation, and categorical variables were reported as a
proportion of the total number of patients. Univariate
analysis was conducted using either a c2 test or Fisher exactPlease cite this article in press as: Lee C-H, et al., Risk factors and clin
resistant only to carbapenems, Journal of Microbiology, Immunology antest for categorical variables, and Student t test or Man-
neWhitney U test for continuous variables, as appropriate.
To eliminate confounding factors in predicting the risk
factors for developing CROPA bacteremia, all variables with
p  0.1 by univariate analysis were entered into a multi-
variate logistic regression model for further assessment. All
statistical calculations were analyzed using SPSS version
18.0 (SPSS Inc., Chicago, IL, USA). Results were expressed
as adjusted odds ratios, and corresponding 95% confidence
interval. All p values were 2-tailed, and p < 0.05 were
considered statistically significant.
Results
Patients and clinical characteristics
A total of 1431 patients with P. aeruginosa bacteremia were
identified during the study period, and only 49 adults had
CROPA bacteremia. We excluded 22 cases of polymicrobial
bacteremia and two cases with a change of in vitro sus-
ceptibility from CROPA to either ASPA or drug-resistant P.
aeruginosa (resistant to aztreonam and ciprofloxacin) in the
follow-up blood cultures. Thus, 25 patients were enrolled
as case patients. All of the 25 CROPA blood isolates from
the case patients had a high-level resistance to imipenem,
including 24 with imipenem MICs >16 mg/mL and one with
an imipenem MIC of 8 mg/mL. Furthermore, 24 of the 25
CROPA isolates had meropenem MICs 4 mg/mL.
A total of 50 control patients were matched. Matching
results, demographics, initial presentations, previously
used antibiotics, and 30-day mortality are shown in Table 1.
There was no significant difference in comorbidities and the
source of bacteremia between the case and control groups
(Table 1). Compared with the control group, the case group
had a longer hospital stay before bacteremia onset (mean:
42.8 days vs. 18.8 days, p Z 0.002), and most of the case
patients acquired infections from nosocomial route (88.0%
vs. 62.0%, p Z 0.02). Pittsburgh bacteremia score was
higher in the case group than the control (3.9  2.5 vs.
2.2  2.3, p Z 0.007).
Prior antibiotic exposure, mainly carbapenems, anti-
pseudomonal cephalosporins and glycopeptides, were more
frequently seen in the case group than the control (68.0%
vs. 8.0%, p < 0.001; 52.0% vs. 22.0%, p Z 0.009; and 52.0%
vs. 20.0%, p Z 0.005; respectively). Seventeen case pa-
tients had ever received carbapenem treatment before
CROPA bacteremia onset and these carbapenems were
administrated for extended-spectrum b-lactamase-pro-
ducing Klebsiella pneumoniae (n Z 7) and Escherichia coli
(n Z 2), drug-resistant Acinetobacter baumannii (n Z 3),
or empirical therapy without identified offending patho-
gens (n Z 5). Multivariate analysis showed that prior car-
bapenem exposure was the only risk factor for CROPA
bacteremia under the model adjusted for the length of
hospital stay, Pittsburgh bacteremia scores, platelet count,
serum creatinine level, and prior exposure to anti-
pseudomonal cephalosporins and glycopeptides (odds ratio,
360.72; 95% confidence interval, 8.101e16061.832;
pZ 0.002; Table 2). The 30-day mortality rate for the caseical significance of bacteremia caused by Pseudomonas aeruginosa
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Table 1 Demographics, clinical characteristics, and outcome analysis of 25 patients with carbapenem resistance-only Pseu-
domonas aeruginosa (CROPA) bacteremia and 50 patients with all-susceptible P. aeruginosa (ASPA) bacteremia.
Variables CROPA (n Z 25) ASPA (n Z 50) p
Demographics
Sex, male 12 (48.0) 24 (48.0) >0.999
Age (y) 61.6  18.3 62.0  17.9 0.935
Length of hospital stay (d) 42.8  37.3 18.8  28.0 0.002
Comorbiditiesa
Diabetes mellitus 10 (40.0) 13 (26) 0.165
Hypertension 9 (36.0) 14 (28) 0.326
End stage renal disease 3 (12) 7 (14) 0.559
Liver cirrhosis 2 (8) 2 (4) 0.407
Solid organ cancer 8 (32) 19 (38) 0.402
Hematologic malignancy 3 (12) 10 (20) 0.302
COPD 3 (12) 4 (8) 0.429
CVA 4 (16) 9 (18) 0.552
Initial presentations
Nosocomial infection 22 (88) 31 (62) 0.020
Pittsburgh score 3.9  2.5 2.2  2.3 0.007
White blood cells (109/L) 10.236  8.417 11.487  8.325 0.541
Haemoglobin (g/dL) 9.6  2.2 9.6  2.2 0.975
Platelet (109/L) 110.9  107.3 159.7  117.1 0.090
C-reactive protein (mg/L) 169.3  161.4 110.9  92.6 0.175
Creatinine (mg/dL) 1.5  1.0 2.2  2.6 0.097
Bacteraemia sourceb
Primary 12 (48) 21 (42) 0.341
Lower respiratory tract infection 10 (40) 9 (18) 0.078
Intra-abdominal infection 0 (0) 2 (4) 0.441
Skin and skin structure infection 0 (0) 2 (4) 0.441
Urinary tract infection 2 (8) 11 (22) 0.115
CRBSI 1 (4) 6 (12) 0.250
Intra-vascular catheters 20 (80) 30 (60) 0.068
Antibiotic exposure within 3 moc
Penicillin class antibiotics 7 (28) 12 (24) 0.707
Aminoglycosides 4 (16) 7 (14) >0.999
Cephalosporins 18 (72) 26 (52) 0.097
Antipseudomonal cephalosporins 13(52) 11 (22) 0.009
Carbapenems 17 (68) 4 (8) <0.001
Fluoroquinolones 6 (24) 5 (10) 0.106
Glycopeptides 13 (52) 10 (20) 0.005
30-day mortality 18 (72) 13 (26) <0.001
a There was no statistic difference in comorbidities and the source of bacteremia between CROPA and ASPA groups.
b There were two patients in the ASPA group having both lower respiratory tract infection and urinary tract infection.
c Penicillin class antibiotics include penicillin, oxacillin, ampicillin, amoxicillineclavulanate, ampicillinesulbactam, piperacillin, and
piperacillinetazobactam. Aminoglycosides include gentamicin and amikacin. Antipseudomonal cephalosporins include ceftazidime,
cefepime, and cefpirome. Carbapenems include ertapenem, imipenem, and meropenem. Fluoroquinolones include moxifloxacin, lev-
ofloxacin, and ciprofloxacin. Glycopeptides include vancomycin and teicoplanin.
Data are presented as n (%) or mean  SD.
COPD Z chronic obstructive pulmonary disease; CRBSI Z catheter-related blood stream infection; CVA Z cerebrovascular accident;
SD Z standard deviation.
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+ MODELpatients was 72.0%, as compared to 26.0% for the controls
(p < 0.001; Table 1).Influence of appropriate antibiotic therapy and the
survival analysis of patients with CROPA bacteremia
A comparison between the surviving and nonsurviving pa-
tients with CROPA bacteremia showed that those who diedPlease cite this article in press as: Lee C-H, et al., Risk factors and clin
resistant only to carbapenems, Journal of Microbiology, Immunology ahad a more severe anemia (9.0  2.0 g/dL vs. 11.2  2.0 g/
dL, p Z 0.042) and a lower platelet count
(72.4  61.8  109/L vs. 226.2  136.8  109/L, pZ 0.01),
but there was no statistical difference in Pittsburgh
bacteremia score between them (Table 3). All those who
survived (7/7, 100%) had an appropriate initial empirical
antibiotic treatment, but more than half of the deceased
patients (10/18, 55.6%) did not have the appropriate initial
empirical antibiotic treatment (p Z 0.02; Table 3). Theical significance of bacteremia caused by Pseudomonas aeruginosa
nd Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.06.003
Table 2 Multivariate analysis of risk factors for carbapenem resistance-only Pseudomonas aeruginosa bacteremia.
Variablesa Odds ratio (95% CI) p
Carbapenem within 3 mob 360.72 (8.101e16061.832) 0.002
Antipseudomonal cephalosporins within 3 moc 0.237 (0.017e3.275) 0.283
Glycopeptides within 3 mod 2.182 (0.339e14.024) 0.411
Hospital stay 0.970 (0.932e1.010) 0.140
Pittsburgh score 1.361 (0.974e1.903) 0.071
Platelet count 1.000 (0.094e1.007) 0.938
Creatinine 0.558 (0.282e1.102) 0.093
a The variables with p < 0.1 in univariate analysis of Table 1 were included in a multivariate regression model.
b Carbapenems include ertapenem, imipenem and meropenem.
c Antipseudomonal cephalosporins include ceftazidime, cefepime, and cefpirome.
d Glycopeptides include vancomycin and teicoplanin.
CI Z confidence interval.
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these 10 deceased patients included imipenem (n Z 6),
meropenem (nZ 1), cefazolin (nZ 1), cefuroxime (nZ 1),
and tigecycline (n Z 1). Among the 18 deceased patients,
nine (50%) received carbapenems as initial empirical anti-
biotic treatment, but none of the survivors received car-
bapenems as initial empirical antibiotic treatment
(p Z 0.027; Table 3).Discussion
Risk factors of developing carbapenem-resistant P. aerugi-
nosa are comorbidities, length of hospital stay, mechanical
ventilation, arterial catheter insertion, prolonged neu-
tropenia, and broad-spectrum antipseudomonal antibiotic
use.6,9,15e17 Most of the carbapenem-resistant P. aerugi-
nosa blood isolates in previous studies had cross-resistance
to other antipseudomonal antibiotics.3,6,7
This study described the clinical characteristics, risk
factors and prognosis of patients with bacteremia caused
by CROPA strains, which have rarely been reported in the
English literature. Under the multiple regression analysis,
prior carbapenem exposure was the only risk factor forTable 3 A comparison between the survived and the deceased
domonas aeruginosa bacteremia.
Variables Dece
Initial presentations
Nosocomial infection 17 (9
Pittsburgh score 4.3 
White blood cells (109/L) 9.18
Haemoglobin (g/dL) 9.0 
Platelet (109/L) 72.4
Creatinine (mg/dL) 1.4 
Treatment
Appropriate initial empirical antibiotics 8 (44
Initial empirical treatment with carbapenemsa 9b (5
a Carbapenems include imipenem and meropenem.
b Seven patients had carbapenem as inappropriate initial empirical
appropriate treatment within 3 days of blood culture collection.
Data are presented as n (%) or mean  SD.
Please cite this article in press as: Lee C-H, et al., Risk factors and clin
resistant only to carbapenems, Journal of Microbiology, Immunology anCROPA bacteremia. The difference between this study and
previous studies is that we chose the patients with ASPA
bacteremia as controls in order to remove the impact of
carbapenem-susceptible P. aeruginosa isolates with varied
susceptibility to other antipseudomonal agents.
The implication and mechanism of this unique pattern of
antibiotic resistance (carbapenem resistance only) in clin-
ical P. aeruginosa isolates are not clear. Shu et al13 con-
ducted a matched-pair study comparing 10 genetically
unrelated CROPA isolates with their counterpart
carbapenem-susceptible strains. Briefly, the protein elec-
trophoresis demonstrated OprD production in only one of
the 10 carbapenem-susceptible isolates, while various oprD
mutations with early terminations were demonstrated in
nine of the 10 CROPA isolates. Besides, RNA analysis
revealed oprM hyperexpression with normal mexA expres-
sion in eight of the carbapenem-susceptible ones, while the
oprM expression was reduced in seven of their CROPA
counterparts. Under antibiotic selective pressure, reduced
production of OprM promoted the selective spontaneous
changes in oprD, leading to the carbapenem resistance in a
group of pan-susceptible P. aeruginosa isolates carrying an
oprD-group 1A allele, particularly imipenem.13 In our study,
17 case patients (68%) had ever received carbapenemamong patients with for carbapenem resistance-only Pseu-
ased (n Z 18) Survived (n Z 7) p
4.4) 5 (71.4) 0.180
2.6 2.6  2.0 0.112
3  9.596 12.942  3.261 0.109
2.0 11.2  2.0 0.042
 61.8 226.2  136.8 0.010
0.8 1.7  1.7 0.649
.4) 7 (100.0) 0.020
0.0) 0 (0.0) 0.027
therapy, and two patients had the change of carbapenems to the
ical significance of bacteremia caused by Pseudomonas aeruginosa
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.06.003
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pressure from carbapenems might be the most important
factor for P. aeruginosa to develop such a type of drug
resistance.
In this study, the all-cause mortality of patients with
CROPA bacteremia was up to 72.0%, which was not only
much higher than that of the control (26.0%), but also
higher than that in previous studies for Pseudomonas
bacteremia, which ranged from 25.2% to 58.8%.2,3,18,19
Compared to carbapenem-susceptible P. aeruginosa
bacteremia, carbapenem-resistant P. aeruginosa bacter-
emia had a higher mortality.16,18,20 Factors for the higher
mortality in patients with P. aeruginosa bacteremia are
nosocomial infection, underlying diseases, severe sepsis,
acute respiratory failure, respiratory tract infection, and
delay in initiating effective antimicrobial therapy.2,3,15,19,21
This study revealed that the appropriateness of empir-
ical antibiotics was associated with a better survival rate by
the 30th day. Similarly, at least two retrospective cohort
studies for patients with P. aeruginosa bloodstream infec-
tion reported that inappropriate empirical antimicrobial
treatment was associated with greater in-hospital mortality
among patients with infections.22,23 In our study, all of the
surviving patients had appropriate initial empirical antibi-
otic treatment, while all of the 10 patients who had
received inappropriate initial empirical antibiotic treat-
ment died, including seven (70%) receiving carbapenems. In
addition to the seven patients, two had initial empirical
antibiotic treatment with carbapenems, and changed car-
bapenems to appropriate antibiotics within 3 days of blood
culture collection. Both of them also died within 2 weeks,
and all nine patients with initial empirical antibiotic
treatment using carbapenems had poor outcome. Thus, it is
advised to prescribe carbapenems carefully and to not
repeat using carbapenems in patients who had carbapenem
treatment for serious infections.
In conclusion, this is the first matched caseecontrol
study focusing on CROPA. CROPA bacteremia was associ-
ated with a high mortality. Prudent use of carbapenem is
the best strategy to reduce the emergence of CROPA in the
hospital setting. Appropriate choice of empirical antibiotic
therapy may have a better survival among patient with
CROPA bacteremia. This study alerts physicians that the
emergence of CROPA in hospital settings could be an issue
of infection control.
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